Evidence map›Paper›PMID 40330829›Full record

ReviewFrontiers in oncology2025

Chemotherapy-free innovations in locally advanced head and neck cancer: a comprehensive review.

Shatha Abu Taha, Taher Abu Hejleh, Mostafa ElHaddad, Akram Al-Ibraheem, Ahmed Abbasi, Abdulrahman Sumaida, Ahmad Bushehri, Ahmad Mostafa, Bassem Youssef, Ibrahim Alotain and 14 more

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Shatha Abu TahaDepartment of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.
Taher Abu HejlehDepartment of Medical Oncology, King Hussein Cancer Center, Amman, Jordan.
Mostafa ElHaddadClinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Akram Al-IbraheemDepartment of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.
Ahmed AbbasiDepartment of Radiation Oncology, Aga Khan University Hospital, Karachi, Pakistan.
Abdulrahman SumaidaOncology: Radiation Oncology, Tawam Hospital, Al Ain, United Arab Emirates.
Ahmad BushehriDepartment of Radiation Oncology, Kuwait Cancer Control Center, Kuwait, Kuwait.
Ahmad MostafaClinical oncology department, Minia Oncology, Center, Minia, Egypt.
Bassem YoussefDepartment of Radiation Oncology, American University of Beirut Medical Centre, Beirut, Lebanon.
Ibrahim AlotainDepartment of Radiation Oncology, King Fahad Specialist, Dammam, Saudi Arabia.
Ibrahim Abu-GheidaDepartment of Radiation Oncology, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
Mohammed AldehaimDepartment of Radiation Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Majed AlghamdiRadiation Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah, Saudi Arabia.
Mohamed ShelanDepartment of Radiation Oncology, Inselspital Bern, University of Bern, Bern, Switzerland.
Mohammed Al DohanDepartment of Radiation Oncology, King Fahad Medical City, Riyadh, Saudi Arabia.
Maysa Al-HussainiDepartment of Cell Therapy and Applied Genomics, King Hussein Cancer Center, Amman, Jordan.
Nadeem PervezDepartment of Radiation Oncology, United Arab Emirates (UAE) University, Al Ain, United Arab Emirates.
Shoukri TemrazClinical Oncology Department, Mansoura University hospital, Mansour, Egypt.
Saad AlrashidiDepartment of Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Wael El-SheshtawyDepartment of Clinical Oncology, Al-Azhar University, Cairo, Egypt.
Zahid Al-MandhariDepartment of Radiation Oncology, Sultan Qaboos Comprehensive Cancer Care and Research Centre, Muscat, Oman.
Hamza GhatashehDepartment of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.
Ali HosniRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Issa MohamadDepartment of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC) has traditionally relied on a multimodal approach, combining surgery, radiation therapy (RT), and chemotherapy. While chemotherapy plays a critical role in improving cure rates and functional outcomes, its substantial toxicity remains a major concern, particularly in older patients. These challenges are especially relevant for those who are unfit for chemotherapy or decline conventional concurrent chemoradiotherapy (CCRT), highlighting the need for alternative therapeutic options. Many patients are at high risk for severe side effects, often preventing them from completing the full chemotherapy regimen. This review explores alternative strategies to definitive CCRT of carcinomas of the larynx, hypopharynx and oropharynx, aiming to optimize treatment outcomes while minimizing toxicity. We discuss altered fractionation strategies as a promising alternative to conventional RT, offering a balance between treatment efficacy and quality of life. Additionally, we examine emerging approaches, including the combining of targeted therapies, immunotherapy, hyperthermia, photodynamic therapy and nanoparticle-based treatments with RT, which provide alternative or complementary options to traditional therapies in the management of LA-HNSCC.

Indexed as

altered fractionationconcurrent chemoradiationhead and neck cancerhyperthermiaimmunotherapynanoparticletargeted therapy

Identifiers

PMID40330829
PMCPMC12052741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.